首页> 美国卫生研究院文献>British Journal of Cancer >HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)
【2h】

HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)

机译:HOX转录因子是非小细胞肺癌的潜在治疗靶标(靶向肺癌中的HOX基因)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The HOX genes are a family of homeodomain-containing transcription factors that determine the identity of cells and tissues during embryonic development. They are also known to behave as oncogenes in some haematological malignancies. In this study, we show that the expression of many of the HOX genes is highly elevated in primary non-small-cell lung cancers (NSCLCs) and in the derived cell lines A549 and H23. Furthermore, blocking the activity of HOX proteins by interfering with their binding to the PBX co-factor causes these cells to undergo apoptosis in vitro and reduces the growth of A549 tumours in vivo. These findings suggest that the interaction between HOX and PBX proteins is a potential therapeutic target in NSCLC.
机译:HOX基因是一个含有同源结构域的转录因子家族,可决定胚胎发育过程中细胞和组织的身份。在某些血液系统恶性肿瘤中,它们也被认为是癌基因。在这项研究中,我们表明,许多HOX基因的表达在原发性非小细胞肺癌(NSCLC)中以及在衍生的细胞系A549和H23中都高度升高。此外,通过干扰HOX蛋白与PBX辅因子的结合来阻断HOX蛋白的活性,导致这些细胞在体外经历凋亡,并在体内减少A549肿瘤的生长。这些发现表明HOX和PBX蛋白之间的相互作用是NSCLC中潜在的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号